Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies
Wenguang Chang, Li Chen, Grant M. Hatch
Biochemistry and Cell Biology (2014) Vol. 93, Iss. 5, pp. 479-486
Closed Access | Times Cited: 141

Showing 1-25 of 141 citing articles:

Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms
Lina Xu, Yue Li, Yan Dai, et al.
Pharmacological Research (2018) Vol. 130, pp. 451-465
Closed Access | Times Cited: 374
Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes
Wen Li, Andrew J. Duffy
Journal of Nutrition (2017) Vol. 147, Iss. 7, pp. 1468S-1475S
Open Access | Times Cited: 338
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics
Xiaojun Feng, Antoni Sureda, Samineh Jafari, et al.
Theranostics (2019) Vol. 9, Iss. 7, pp. 1923-1951
Open Access | Times Cited: 319
The strategies and techniques of drug discovery from natural products
Li Zhang, Junke Song, Ling-Lei Kong, et al.
Pharmacology & Therapeutics (2020) Vol. 216, pp. 107686-107686
Closed Access | Times Cited: 175
The Pathogenesis of Diabetes Mellitus by Oxidative Stress and Inflammation: Its Inhibition by Berberine
Xueling Ma, Zhongjun Chen, Le Wang, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 165
Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases
Menghang Zu, Ya Ma, Brandon Cannup, et al.
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113887-113887
Closed Access | Times Cited: 127
Nrf2 Pathway and Oxidative Stress as a Common Target for Treatment of Diabetes and Its Comorbidities
Michelle Yi, L Cisneros, E.J. Cho, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 821-821
Open Access | Times Cited: 16
Diabetes and plant‐derived natural products: From ethnopharmacological approaches to their potential for modern drug discovery and development
Arun K. Jugran, Sandeep Rawat, Hari Prasad Devkota, et al.
Phytotherapy Research (2020) Vol. 35, Iss. 1, pp. 223-245
Closed Access | Times Cited: 115
Berberine enhances the AMPK activation and autophagy and mitigates high glucose-induced apoptosis of mouse podocytes
Yingli Jin, Shuping Liu, Qingshan Ma, et al.
European Journal of Pharmacology (2016) Vol. 794, pp. 106-114
Closed Access | Times Cited: 109
Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy
Saikat Dewanjee, Pratik Chakraborty, Biswajit Mukherjee, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 2217-2217
Open Access | Times Cited: 108
Berberine inhibits NLRP3 Inflammasome pathway in human triple-negative breast cancer MDA-MB-231 cell
Mingjiang Yao, Xiaodi Fan, Bo Yuan, et al.
BMC Complementary and Alternative Medicine (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 102
Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis
Yaping Liang, Xiaojia Xu, Mingjuan Yin, et al.
Endocrine Journal (2018) Vol. 66, Iss. 1, pp. 51-63
Open Access | Times Cited: 96
Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways
Yunli Yu, Gang Hao, Zhang Quan-ying, et al.
Biochemical Pharmacology (2015) Vol. 97, Iss. 2, pp. 173-177
Closed Access | Times Cited: 92
Berberine suppresses colon cancer cell proliferation by inhibiting the SCAP/SREBP-1 signaling pathway-mediated lipogenesis
Yunxin Liu, Weiwei Hua, Yao Li, et al.
Biochemical Pharmacology (2019) Vol. 174, pp. 113776-113776
Closed Access | Times Cited: 90
Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis
Wenting Xie, Fugui Su, Wang Gui-zhong, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 39
A Review of Fibraurea tinctoria and Its Component, Berberine, as an Antidiabetic and Antioxidant
Indah Purwaningsih, Iman Permana Maksum, Dadan Sumiarsa, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1294-1294
Open Access | Times Cited: 32
Berberine and Its Study as an Antidiabetic Compound
Ayudiah Rizki Utami, Iman Permana Maksum, Yusi Deawati
Biology (2023) Vol. 12, Iss. 7, pp. 973-973
Open Access | Times Cited: 28
Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway
Shengnan Wei, Ming Zhang, Yang Yu, et al.
PLoS ONE (2016) Vol. 11, Iss. 3, pp. e0152097-e0152097
Open Access | Times Cited: 74
Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5′-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells
Wenguang Chang, Ming Zhang, Zhaojie Meng, et al.
European Journal of Pharmacology (2015) Vol. 769, pp. 55-63
Closed Access | Times Cited: 71
Composition and diversity of rhizosphere fungal community in Coptis chinensis Franch. continuous cropping fields
Xu-Hong Song, Yuan Pan, Longyun Li, et al.
PLoS ONE (2018) Vol. 13, Iss. 3, pp. e0193811-e0193811
Open Access | Times Cited: 67
Therapeutic medications against diabetes: What we have and what we expect
Cheng Hu, Weiping Jia
Advanced Drug Delivery Reviews (2018) Vol. 139, pp. 3-15
Open Access | Times Cited: 63
Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential
Dahua Fan, Liping Liu, Zhengzhi Wu, et al.
Current Neuropharmacology (2018) Vol. 17, Iss. 6, pp. 563-579
Open Access | Times Cited: 62
Non-coding RNAs and Berberine: A new mechanism of its anti-diabetic activities
Wenguang Chang
European Journal of Pharmacology (2016) Vol. 795, pp. 8-12
Closed Access | Times Cited: 61
Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids
Ye Yao, Han Chen, Lijing Yan, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 131, pp. 110669-110669
Open Access | Times Cited: 55
Pyrrolidine alkaloids and their promises in pharmacotherapy
Muhammad Torequl Islam, Mohammad S. Mubarak
Advances in Traditional Medicine (2020) Vol. 20, Iss. 1, pp. 13-22
Closed Access | Times Cited: 54
Page 1 - Next Page

Scroll to top